Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adverse Event Reports From Acorda Languished As Long As 100 Days, FDA Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA warning letter says the company did not report all complaints about the lack of efficacy of its muscular sclerosis drug Ampyra.

Advertisement

Related Content

Warning Letter On Adverse Event Reporting May Stem As Much From Jazz Reaction As REMS Problem
Sanofi Still Needs Fix For Adverse Event Reporting As FDA Seeks Retrospective Study, Pinches Accenture

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel